A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI114, in patients with advanced cancer

被引：0
|
作者：
Eckhardt, SG
Baker, SD
Moczygemba, J
MacDonald, JR
Smith, S
Von Hoff, DD
Rowinsky, EK
机构：
[1] Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[2] MGI Pharma, Minnetonka, MN USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
471
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114, in combination with irinotecan in patients with advanced cancer.
    Eckhardt, SG
    Kuhn, JG
    Britten, CD
    Weitman, S
    Baker, SD
    MacDonald, JR
    Newman, A
    Smith, S
    Von Hoff, DD
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 1999, 5 : 3793S - 3793S
  • [2] Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
    Eckhardt, SG
    Baker, SD
    Britten, CD
    Hidalgo, M
    Siu, L
    Hammond, LA
    Villalona-Calero, MA
    Felton, S
    Drengler, R
    Kuhn, JG
    Clark, GM
    Smith, SL
    MacDonald, JR
    Smith, C
    Moczygemba, J
    Weitman, S
    Von Hoff, DD
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) : 4086 - 4097
  • [3] A phase I and pharmacokinetic (PK) study of the rebeccamycin analog NSC 655649 in patients with advanced cancer
    Eckhardt, SG
    Kuhn, J
    Rizzo, J
    Sharma, S
    Campbell, E
    Ivey, P
    Weiss, G
    Hammond, L
    Kraynak, M
    Von Hoff, DD
    Rowinsky, EK
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
  • [4] Phase I trial and pharmacokinetic (PK) analysis of depsipeptide in patients with advanced cancer
    Marshall, JL
    Dahut, WL
    Rizvi, N
    Wainer, IW
    Chassaing, C
    Figuiera, M
    Hawkins, MJ
    ANNALS OF ONCOLOGY, 1998, 9 : 123 - 123
  • [5] MGI Pharma initiates phase II study of MGI-114 in pancreatic cancer patients
    不详
    DRUG NEWS & PERSPECTIVES, 1998, 11 (09) : 522 - 522
  • [6] A phase I and pharmacokinetic (PK) study of the polyamine biosynthesis inhibitor CGP 48664 in patients with advanced cancer
    Siu, LL
    Rowinsky, EK
    Weiss, GR
    Hammond, L
    Kraynak, M
    Moczygemba, J
    Choi, L
    Linnartz, R
    Porter, C
    DeMoor, C
    Von Hoff, DD
    Eckhardt, SG
    ANNALS OF ONCOLOGY, 1998, 9 : 116 - 116
  • [7] Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study
    Rudek, MA
    Donehower, RC
    Statkevich, P
    Batra, VK
    Cutler, DL
    Baker, SD
    PHARMACOTHERAPY, 2004, 24 (01): : 16 - 25
  • [8] Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
    LoRusso, Patricia M.
    Jones, Suzanne F.
    Koch, Kevin M.
    Arya, Nikita
    Fleming, Ronald A.
    Loftiss, Jill
    Pandite, Lini
    Gadgeel, Shirish
    Weber, Barbara L.
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 3051 - 3056
  • [9] Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
    Giles, F
    Cortes, J
    Garcia-Manero, G
    Kornblau, S
    Estey, E
    Kwari, M
    Murgo, A
    Kantarjian, H
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) : 13 - 20
  • [10] Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia
    Francis Giles
    Jorge Cortes
    Guillermo Garcia-Manero
    Stephen Kornblau
    Elihu Estey
    Monica Kwari
    Anthony Murgo
    Hagop Kantarjian
    Investigational New Drugs, 2001, 19 : 13 - 20
12345